SCHEMBL418942

SCHEMBL418942

CC1(C)OCC(CCO)O1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.44
ALDH1A1 P00352 4/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TMEM97 Q5BJF2 2/20 0.36
SIGMAR1 Q99720 2/20 0.36
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM3 P20309 1/20 0.34
MAPT P10636 3/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 1/20 0.33
MEN1 O00255 1/20 0.31
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31
PKM P14618 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
MAPK1 P28482 1/20 0.31
CASP1 P29466 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368709 1.00 CA2 (0.44) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL649656 1.00 CA2 (0.44) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL4929770 0.88 CA2 (0.42) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL929572 0.88 CA2 (0.42) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL1243925 0.88 CA2 (0.42) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL7154999 0.86 CA2 (0.50) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL18817541 0.86 CA2 (0.50) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL714194 0.86 CA2 (0.41) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL20707235 0.86 CA2 (0.41) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL21409717 0.84 CA2 (0.40) CA2ALDH1A1NPSR1TMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4640769-A1 CONDUCTIVE POLYMER-CONTAINING DISPERSION, SOLID ELECTROLYTE CAPACITOR, AND PRODUCTION METHOD FOR SAME Resonac Corporation (JP) 2025-10-29 EP claimed
US-12312480-B2 Aqueous ink, ink cartridge and ink jet recording method CANON KABUSHIKI KAISHA (JP) 2025-05-27 US claimed
WO-2024135579-A1 CONDUCTIVE POLYMER-CONTAINING DISPERSION, SOLID ELECTROLYTE CAPACITOR, AND PRODUCTION METHOD FOR SAME 株式会社レゾナック 2024-06-27 WO claimed
CN-111518561-B Silicon etchant and application thereof 才将科技股份有限公司 2021-09-28 CN claimed
US-11084981-B2 Silicon etchant with high Si/SiO2 etching selectivity and application thereof CJ TECHNOLOGY CO., LTD. (TW) 2021-08-10 US claimed
CN-111518561-A Silicon etchant and application thereof 才将科技股份有限公司 2020-08-11 CN claimed
US-20200248074-A1 Silicon etchant with high Si/SiO2 etching selectivity and Application thereof CJ TECHNOLOGY CO., LTD. (TW) 2020-08-06 US claimed
EP-2619179-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP claimed
EP-2460842-A2 Novel energetic polyphosphazenes The Secretary of State For Defence (GB) 2012-06-06 EP claimed
WO-2012038944-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO claimed
WO-2010048536-A2 PROCESSES FOR PREPARING LIPIDS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-04-29 WO claimed
EP-1960456-A1 NOVEL ENERGETIC POLYPHOSPHAZENES THE SECRETARY OF STATE FOR DEFENCE (GB) 2008-08-27 EP claimed
WO-2006032882-A1 NOVEL ENERGETIC POLYPHOSPHAZENES THE SECRETARY OF STATE FOR DEFENCE (GB) 2006-03-30 WO claimed
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2026-05-28 US disclosed
EP-4003988-B1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS SERVIER LAB (FR) 2026-05-20 EP disclosed
US-20260130921-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS AcuraStem Incorporated (US) 2026-05-14 US disclosed
US-4595690-A Hypotensive agents SYNTEX (U.S.A.) INC. (US) 1986-06-17 US disclosed
US-4576905-A Photographically useful chalcogenazoles, chalcogenazolines, and chalcogenazolinium and chalcogenazolium salts EASTMAN KODAK COMPANY (US) 1986-03-18 US disclosed
EP-0138362-A2 Photographic materials containing chalcogenazoles, chalcogenazolines and chalcogenazolinium and chalcogenazolium salts EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-04-24 EP disclosed
EP-0136847-A2 Photographically useful chalcogenazolylidene and chalcogenazolium dyes and methods for their preparation EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS AXL, ERBB2, ERBB3 CA2 476/4885ALDH1A1 2378/4885NPSR1 1431/4885
US-20260130921-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS TMPRSS2, TMPRSS11D, TMPRSS6 CA2 778/4885ALDH1A1 4774/4885NPSR1 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.